Rituxan injection drug use-results survey in patients with complicated nephrotic syndrome

Rituxan injection drug use-results survey in patients with complicated nephrotic syndrome - Rituxan injection drug use-results survey in patients with complicated nephrotic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014997

Enrollment

300

Registered

2014-08-29

Start date

2014-08-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotic symdrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients who have received rituximab for nephrotic syndrome

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Adverse drug reaction occurrences Relapse-free period	—

Countries

Japan

Contacts

Public ContactShohji Kimura

Zenyaku Kogyo, Co., Ltd. Post-Marketing-Surveillance Pharmacovigilance & Quality Assurance Department

Shohji_Kimura@mail.zenyaku.co.jp03-3946-1136

Outcome results